Week In Review: Innovent Acquires GenFleet's KRAS G12C Oncology Candidate In $312 Million Deal
September 04, 2021 at 15:47 PM EDT
Suzhou Innovent acquired greater China rights to GenFleet's lead KRAS G12C oncology candidate in a $312 million agreement. Innovent will pay $22 million upfront and make up to $240 million in milestone payments.
